GlassScriptPhysician profile
Heather A Layher
NPI 1851658355
$1,823.93
in general payments reported to CMS, 2019-2025
17 companies · $184 in 2025
The $184 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $177 · 2021: $593 · 2022: $339 · 2023: $213 · 2024: $318 · 2025: $184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $716.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $715.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $515.84 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $193.96 | 2021-2024 | Dupixent |
| Amgen INC. | $193.80 | 2020-2021 | |
| Galderma Laboratories, L.P. | $124.83 | 2020 | |
| Ucb, INC. | $124.49 | 2022-2025 | Bimzelx |
| Novo Nordisk INC | $122.79 | 2024 | Wegovy |
| Lilly USA, LLC | $112.24 | 2021-2022 | |
| Janssen Biotech, INC. | $100.56 | 2020-2023 | Tremfya |
| Incyte Corporation | $76.82 | 2022-2024 | Opzelura |
| Mimedx Group, INC. | $47.81 | 2024 | |
| Janssen Scientific Affairs, LLC | $42.35 | 2024 | Tremfya |
| Genzyme Corporation | $40.15 | 2023 | |
| Revance Therapeutics, INC. | $35.16 | 2025 | Daxxify |
| Sun Pharmaceutical Industries INC. | $32.50 | 2020-2025 | |
| Reprise Biomedical, INC. | $31.73 | 2025 | Miro3d |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $18.73 | 2025 | Adbry |
| Sensus Healthcare, INC. | $10.17 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Layher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.